Rapamycin reduces oxidative stress in frataxin-deficient yeast cells
Abstract
Friedreich ataxia (FRDA) is a common form of ataxia caused by decreased expression of the mitochondrial protein frataxin. Oxidative damage of mitochondria is thought to play a key role in the pathogenesis of the disease. Therefore, a possible therapeutic strategy should be directed to an antioxidant protection against mitochondrial damage. Indeed, treatment of FRDA patients with the antioxidant idebenone has been shown to improve neurological functions. The yeast frataxin knock-out model of the disease shows mitochondrial iron accumulation, iron-sulfur cluster defects and high sensitivity to oxidative stress. By flow cytometry analysis we studied reactive oxygen species (ROS) production of yeast frataxin mutant cells treated with two antioxidants, N-acetyl-L-cysteine and a mitochondrially-targeted analog of vitamin E, confirming that mitochondria are the main site of ROS production in this model. Furthermore we found a significant reduction of ROS production and a decrease in the mitochondrial mass in mutant cells treated with rapamycin, an inhibitor of TOR kinases, most likely due to autophagy of damaged mitochondria.
Autore Pugliese
Tutti gli autori
-
MAROBBIO C.M.;PISANO I.;PALMIERI L.;PORCELLI V.
Titolo volume/Rivista
Non Disponibile
Anno di pubblicazione
2012
ISSN
1567-7249
ISBN
Non Disponibile
Numero di citazioni Wos
21
Ultimo Aggiornamento Citazioni
Non Disponibile
Numero di citazioni Scopus
23
Ultimo Aggiornamento Citazioni
Non Disponibile
Settori ERC
Non Disponibile
Codici ASJC
Non Disponibile
Condividi questo sito sui social